Hematologic Oncology | Specialty

Glasdegib, Gilteritinib, and Quizartinib Against AML

January 8th 2019

Venetoclax for CLL After Progression on 1 Prior Therapy

January 8th 2019

Midostaurin Plus Chemotherapy for FLT3-Mutated AML Cases

January 8th 2019

Efficacy and Safety of Ibrutinib-Containing Regimens in CLL

January 8th 2019

Mutational Drivers of Acute Myeloid Leukemia

January 8th 2019

Treatment Options for Chronic Lymphocytic Leukemia

January 8th 2019

Dr. Madduri on the Standard of Care for Transplant Eligible Patients With Myeloma

January 8th 2019

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the standard of care for transplant eligible patients with multiple myeloma.

Lilly Acquires Loxo Oncology in $8 Billion Deal

January 8th 2019

Eli Lilly and Company has announced that it will acquire the biopharmaceutical company Loxo Oncology for $235 per share in cash or an estimated $8 billion.

Finding a Place for Stimulatory Immune Checkpoint Antibodies

January 7th 2019

When it works, immunotherapy can dramatically outperform standard of care—for some cancer types, in ways thought unattainable a decade ago.

Bristol-Myers Squibb Acquires Celgene Corporation

January 4th 2019

Bristol-Myers Squibb (BMS) has entered into a definitive merger agreement with Celgene Corporation under which BMS will acquire Celgene in a cash and stock transaction with an equity value of about $74 billion.

Added Factors Put the Overall Survival Endpoint to the Test

January 3rd 2019

The impact of subsequent lines of treatment on trial outcomes can be substantial, seriously challenging the relevance of OS as an objectively meaningful study endpoint.

FDA Approves Dasatinib for Pediatric Ph+ ALL

January 3rd 2019

The FDA has approved dasatinib tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Dr. Pikman on Matching Pediatric Patients With More Precise Leukemia Therapy

December 28th 2018

Yana Pikman, MD, a physician in the Cancer and Blood Disorders Center at Dana-Farber Cancer Institute and instructor of pediatrics at Harvard Medical School, discusses a trial attempting to match pediatric patients with more precise therapy for acute leukemia.

FDA Approves Ravulizumab for Paroxysmal Nocturnal Hemoglobinuria

December 27th 2018

The FDA has approved ravulizumab-cwvz as an injection treatment of adult patients with paroxysmal nocturnal hemoglobinuria, a rare blood disorder that leads to hemolysis.

Dr. Andreeff Discusses Promise of Venetoclax in AML

December 21st 2018

Michael Andreeff, MD, PhD, chair of genetics, professor of medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the promise of venetoclax in acute myeloid leukemia.

FDA Approves Tagraxofusp for Rare Hematologic Cancer

December 21st 2018

The FDA has approved tagraxofusp-erzs infusion for the treatment of adult and pediatric patients, aged ≥2 years, with blastic plasmacytoid dendritic cell neoplasm.

Dr. Jagannath on Cancer Proliferation in Multiple Myeloma

December 21st 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses cancer proliferation in multiple myeloma.

Dr. Chari on PVd for Relapsed Patients With Multiple Myeloma

December 18th 2018

Ajai Chari, MD, associate professor of Medicine, Hematology and Medical Oncology, at Mount Sinai Hospital, discusses the use of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone (PVd) for relapsed patients with multiple myeloma.

Dr. Cho on the Knowledge Deficit in Multiple Myeloma

December 15th 2018

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses the knowledge deficit in multiple myeloma.

EU Panel Backs Brentuximab Vedotin for Frontline CD30+ Hodgkin Lymphoma

December 15th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with CD30+ stage IV Hodgkin lymphoma.